Status:
UNKNOWN
Stopping Antiviral Treatment in Chronic Hepatitis B
Lead Sponsor:
The University of Hong Kong
Conditions:
Chronic Hepatitis b
Eligibility:
All Genders
18+ years
Brief Summary
Chronic hepatitis B (CHB) infection affected 292 million individuals in the world, translating to about 3.9% of global prevalence. Up to 40% of patients with CHB will develop liver-related complicatio...
Detailed Description
Chronic hepatitis B infection (CHB) affected 292 million individuals in the world in 2016 according to the Polaris Observatory estimation, translating to about 3.9% global prevalence. Up to 40% of pat...
Eligibility Criteria
Inclusion
- HBeAg-negative
- non-cirrhotic
- on long-term NA ≥3 years (entecavir or tenofovir)
- undetectable serum HBV DNA
Exclusion
- HCC, cirrhosis, history of liver transplantation, or on immunosuppressants,
Key Trial Info
Start Date :
June 1 2021
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 31 2024
Estimated Enrollment :
54 Patients enrolled
Trial Details
Trial ID
NCT04431245
Start Date
June 1 2021
End Date
December 31 2024
Last Update
May 10 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Man Fung Yuen
Hong Kong, Please Select One ..., Hong Kong